---
document_datetime: 2024-10-24 11:43:37
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/jylamvo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: jylamvo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.0115808
conversion_datetime: 2025-12-29 19:15:14.265816
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Jylamvo

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0023/G          | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 21/10/2024                          |                                             | Annex II and PL                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site   |            |            |                        |                                                                                                                                           |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2014/ 202310 | Periodic Safety Update EU Single assessment - methotrexate                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 27/06/2024 | 22/08/2024 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2014/202310. |
| T/0022             | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 03/06/2024 | 05/07/2024 | SmPC, Labelling and PL |                                                                                                                                           |
| IB/0020            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                         | 30/03/2023 | 16/02/2024 | SmPC and PL            |                                                                                                                                           |
| IA/0019            | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 25/01/2023 | 16/02/2024 | SmPC                   |                                                                                                                                           |
| PSUSA/2014/ 202110 | Periodic Safety Update EU Single assessment - methotrexate                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 10/06/2022 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                         |
| IB/0017            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                         | 24/02/2022 | 21/11/2022 | SmPC and PL            | Update of Section 4.4 of the SmPC and of the PL by adding revised wording on liver function tests.                                        |

<div style=\"page-break-after: always\"></div>

| IAIN/0016   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 23/11/2021   | 21/11/2022   | SmPC and PL            |                                                                                                                                                                                                                                                                       |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0015      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 16/09/2021   | 22/11/2021   |                        | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Jylamvo in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IAIN/0014   | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 14/04/2021   | 22/11/2021   | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                       |
| IAIN/0013/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 15/01/2021   | 22/11/2021   | Annex II and PL        |                                                                                                                                                                                                                                                                       |
| IB/0012     | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 04/01/2021   | 22/11/2021   | SmPC                   |                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| PSUSA/2014/ 201910   | Periodic Safety Update EU Single assessment - methotrexate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 28/05/2020   | 10/08/2020   | SmPC and PL                  | Please refer to Jylamvo - Nordimet EMEA/H/C/PSUSA/00002014/201910 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation.   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0010              | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 20/12/2019   | n/a          |                              |                                                                                                                                                                                      |
| A31/0002             | Pursuant to Article 31 of Directive 2001/83/EC, Spain requested on 22 March 2018 the opinion of the European Medicines Agency further to serious cases of overdose, sometimes fatal, having been reported in patients inadvertently receiving the product daily instead of weekly for indications that require weekly dosing despite additional risk minimisation measures having been put in place by several Member States. The CHMP was requested to assess the impact thereof on the benefit-risk balance of methotrexate- containing medicinal products and to give its recommendation whether the marketing authorisation of these products should be maintained, varied, suspended or revoked. As the request results from the evaluation of data resulting from pharmacovigilance activities, the CHMP opinion should be adopted on the basis of a recommendation of the Pharmacovigilance Risk Assessment Committee (PRAC). | 22/08/2019   | 21/10/2019   | SmPC, Annex II and Labelling | Please refer to the assessment report: Jylamvo EMEA/H/A-31/1463/C/3756/0002 Nordimet EMEA/H/A-31/1463/C/3983/0006                                                                    |

<div style=\"page-break-after: always\"></div>

| IAIN/0008/G        | This was an application for a group of variations.                                                                                                                                                                                                                                                                                    | 05/09/2019   | 10/08/2020   | Annex II and PL   |                                                                                                                                                                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2014/ 201810 | Periodic Safety Update EU Single assessment - methotrexate                                                                                                                                                                                                                                                                            | 27/06/2019   | 26/08/2019   | SmPC and PL       | Please refer to Jylamvo - Nordimet EMEA/H/C/PSUSA/00002014/201810 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation |
| II/0005/G          | This was an application for a group of variations. B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range | 25/07/2019   | 21/10/2019   | SmPC              |                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| T/0007             | Transfer of Marketing Authorisation                                                              | 15/03/2019   | 29/03/2019   | SmPC, Labelling and PL   |                                                                                                                                           |
|--------------------|--------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| N/0004             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 24/01/2019   | 28/03/2019   | Labelling                |                                                                                                                                           |
| PSUSA/2014/ 201706 | Periodic Safety Update EU Single assessment - methotrexate                                       | 22/03/2018   | 22/05/2018   | SmPC and PL              | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2014/201706. |
| IAIN/0003          | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation   | 24/04/2018   | 28/03/2019   | SmPC and PL              |                                                                                                                                           |